Moderna Inc (NQ: MRNA )
103.31 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2023 Add to My Watchlist
Press Releases about Moderna Inc
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...
Two Appealing Biotech Stocks for Two Distinct investors
August 08, 2022
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
July 29, 2022
New U.S. government contract includes an award up to $1.74 billion for 66 million doses to be delivered in 2022; additional options, if exercised, may raise total to 300 million doses
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
July 22, 2022
CAMBRIDGE, MA / ACCESSWIRE / July 22, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines...
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
July 18, 2022
Announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active immunization to prevent COVID-19 caused by SARS-CoV-2 in...
Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives.
CAMBRIDGE, MA / ACCESSWIRE / July 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live...
Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster
July 11, 2022
mRNA-1273.214 has now demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants, ancestral virus, Alpha, Beta, Delta, and Gamma
Exposures Product Safety
Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5
June 22, 2022
mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study
Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
June 17, 2022
mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
June 08, 2022
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
June 07, 2022
mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trialmRNA-1010 is one of several influenza vaccine candidates being developed in Moderna's respiratory...
Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement
June 02, 2022
CAMBRIDGE, MA / ACCESSWIRE / June 2, 2022 / Moderna, Inc.(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the European...
Moderna to Present at Upcoming Conferences in June 2022
June 01, 2022
CAMBRIDGE, MA / ACCESSWIRE / June 1, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the...
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
May 31, 2022
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,...
CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a...